IMARA

Imara, Inc. is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687, is a selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Brookline, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” -- -- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. (“Enliven”) pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the “Merger”).

Imara Announces Stockholder Approval of Merger With Enliven

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Imara Inc. (the “Company”) (NasdaqGS: IMRA) with Enliven Therapeutics, Inc. Under the terms of the proposed transaction, shareholders of Imara are expected to own only approximately 16% of the combined company, subject to certain adjustments. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company's shareholders.

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

AST SpaceMobile

180 Life Sciences 

Cosmos Holdings

Canoo

Marathon Digital Holdings

Redfin

Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?

Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch

First Eagle Alternative Capital BDC Inc

KnowBe4

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: First Eagle Alternative Capital BDC, Inc. (NASDAQ: FCRD)'s  sale to Crescent Capital BDC, Inc. If you are a First Eagle shareholder, click here to learn more about your rights and options . KnowBe4, Inc. (NASDAQ: KNBE)'s  sale to Vista Equity Partners for $24.90 per share in cash.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FCRD, KNBE, IMRA

Black Diamond Therapeutics

Local Bounti Corp

Penny stock picks from Insiders in October 2022. The post 4 Penny Stocks To Buy: Insider Picks For October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy: Insider Picks For October

Cabaletta Bio

Ngm Biopharmaceuticals Inc

Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Best Penny Stocks To Buy Before November According To Insiders

Agrify

Avenue Therapeutics

Are these methods part of your penny stocks trading strategy The post New to Trading Penny Stocks? Must Knows in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

New to Trading Penny Stocks? Must Knows in 2022

NEW YORK , Oct. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IMARA Inc. ("IMARA" or the "Company") (NASDAQ: IMRA) in connection with the proposed merger of the Company with Enliven Therapeutics, Inc. ("Enliven"). Under the terms of the merger agreement, IMARA will issue IMARA common stock as merger consideration in exchange for the cancellation of shares of capital stock of Enliven and Enliven will become a wholly owned subsidiary of IMARA.

SHAREHOLDER ALERT: Weiss Law Investigates IMARA Inc.

Imara (NASDAQ: IMRA ) stock is rocketing higher on Friday after the company revealed plans for a merger agreement with Enliven Therapeutics. The merger agreement will involve no cash and instead see the two companies use stock to fuel the deal.

Imara (IMRA) Stock Soars 35% on Merger Agreement

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Imara Inc. (NASDAQ: IMRA) and Enliven Therapeutics, Inc. is fair to Imara shareholders.

IMRA Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Imara Inc. is Fair to Shareholders

Boulder, CO and Boston, MA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) (Imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001, a highly selective small molecule BCR-ABL inhibitor designed to address the challenges that limit the efficacy, tolerability and convenience of currently available adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML), and ELVN-002, a potent, selective and irreversible HER2 and pan-HER2 mutant kinase inhibitor for the treatment of HER2 mutant lung cancer and other HER2-driven tumor types. Upon completion of the merger, which is subject to approval by Imara's and Enliven's stockholders, the combined company is expected to operate under the name Enliven Therapeutics, Inc. and trade on the Nasdaq Global Select Market under the ticker symbol ELVN.

Enliven Therapeutics and Imara Announce Merger Agreement

Imara has announced strategic alternatives and has announced the sale its key asset. It now trades 37% below its Pro Forma net cash levels and a liquidation would be ideal.

Imara: Potential Liquidation

Here is how IMARA Inc. (IMRA) and Viracta (VIRX) have performed compared to their sector so far this year.

Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?

Rubius Therapeutics Inc

VistaGen Therapeutics

Here's what you need to know about buying penny stocks on September 9th, 2022 The post 3 High Volume Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 High Volume Penny Stocks To Watch Before Next Week

Bird Rides

Ginkgo Bioworks Holdings

FuboTV

Lufax Holding

PLBY Group

Party City Holdco

Sorrento Therapeutics Inc

Tellurian

Vroom

Penny stocks to watch today with unusual options action. The post 10 Top Penny Stocks With Unusual Options Activity This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks With Unusual Options Activity This Week

Mullen Automotive

Spero Therapeutics

Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?

Looking for Popular Penny Stocks to Buy? 3 to Watch Now

Penny stocks to watch with unusual options activity today. The post 5 Top Penny Stocks With Unusual Options Activity Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks With Unusual Options Activity Today

IMARA Inc. (IMRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes IMARA Inc. (IMRA) a New Buy Stock

Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia.  Data from the sickle cell disease study interim analysis demonstrated that.

Read Why Imara Shares Are Falling Today

Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022

Imara Reports Full Year 2021 Financial Results and Business Highlights

Akebia Therapeutics

Amylyx Pharmaceuticals

Arena Pharmaceuticals

Ascendis Pharma

Bristol-Myers

Terns Pharmaceuticals

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.

7 Biotech Stocks With Key Catalysts in March

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights.

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Sensei Biotherapeutics

US Xpress Enterprises

Insiders are scooping up these penny stocks in February. The post Best Penny Stocks To Buy?

News for IMARA Stock (IMRA)